Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · Real-Time Price · USD
244.25
-2.15 (-0.87%)
At close: Jul 21, 2025, 4:00 PM
244.69
+0.44 (0.18%)
After-hours: Jul 21, 2025, 7:00 PM EDT
Bio-Rad Laboratories Stock Forecast
Stock Price Forecast
The 4 analysts that cover Bio-Rad Laboratories stock have a consensus rating of "Strong Buy" and an average price target of $324.25, which forecasts a 32.75% increase in the stock price over the next year. The lowest target is $245 and the highest is $392.
Price Target: $324.25 (+32.75%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 9, 2025.
Analyst Ratings
The average analyst rating for Bio-Rad Laboratories stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $260 → $245 | Hold | Maintains | $260 → $245 | +0.31% | Jun 9, 2025 |
| UBS | UBS | Strong Buy Maintains $355 → $310 | Strong Buy | Maintains | $355 → $310 | +26.92% | May 2, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $400 → $350 | Strong Buy | Maintains | $400 → $350 | +43.30% | May 2, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $409 → $392 | Buy | Maintains | $409 → $392 | +60.49% | May 2, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $320 → $270 | Hold | Maintains | $320 → $270 | +10.54% | Apr 17, 2025 |
Financial Forecast
Revenue This Year
2.54B
from 2.57B
Decreased by -0.88%
Revenue Next Year
2.63B
from 2.54B
Increased by 3.42%
EPS This Year
8.52
from -65.36
EPS Next Year
9.37
from 8.52
Increased by 9.95%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.7B | 2.8B | 2.9B | ||
| Avg | 2.5B | 2.6B | 2.7B | ||
| Low | 2.4B | 2.5B | 2.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.1% | 9.0% | 11.5% | ||
| Avg | -0.9% | 3.4% | 4.2% | ||
| Low | -4.7% | -1.7% | -1.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.69 | 10.83 | 13.34 | ||
| Avg | 8.52 | 9.37 | 10.78 | ||
| Low | 7.33 | 7.30 | 7.78 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 27.0% | 42.3% | ||
| Avg | - | 9.9% | 15.1% | ||
| Low | - | -14.3% | -17.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.